Cargando…
Successful Combination of Olaparib and (225)Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
Based on the results of the NETTER-1 trial, peptide receptor radionuclide therapy with Lutetium-177 ((177)Lu) – DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and grade 2 (G2) of the intestine. After the failure of (177)Lu-DOTATATE therapy, targeted alpha-partic...
Autores principales: | Kröcher, Anke, Folprecht, Gunnar, Winzer, Robert, Sergon, Mildred, Bornhäuser, Martin, Kotzerke, Jörg, Brogsitter, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601768/ https://www.ncbi.nlm.nih.gov/pubmed/37900794 http://dx.doi.org/10.1159/000533198 |
Ejemplares similares
-
Ac-EAZY! Towards GMP-Compliant Module Syntheses of (225)Ac-Labeled Peptides for Clinical Application
por: Pretze, Marc, et al.
Publicado: (2021) -
Initial Findings on the Use of [(225)Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors
por: Demirci, Emre, et al.
Publicado: (2023) -
Almost Complete Response with a Single Administration (225)Ac-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary
por: Alan Selçuk, Nalan, et al.
Publicado: (2022) -
Efficacy and safety of (225)Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study
por: Yadav, Madhav Prasad, et al.
Publicado: (2021) -
(225)Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic
por: Rubira, Léa, et al.
Publicado: (2023)